

Title (en)

FLAVONOID COMPOSITION FOR TREATING ORAL DISEASES

Title (de)

FLAVONOIDZUSAMMENSETZUNG ZUR BEHANDLUNG ORALER ERKRANKUNGEN

Title (fr)

COMPOSITION FLAVONOIDE POUR LE TRAITEMENT DES MALADIES BUCCO-DENTAIRES

Publication

EP 1804787 A4 20090114 (EN)

Application

EP 05810437 A 20051019

Priority

- US 2005037936 W 20051019
- US 62016304 P 20041019

Abstract (en)

[origin: WO2006045056A2] The present invention provides a novel composition of matter comprised of a mixture of two specific classes of compounds --Free-B-Ring flavonoids and flavans-- for use in the prevention and treatment of diseases and conditions associated with mouth, gums and teeth. This composition of matter simultaneously inhibits cyclooxygenase (COX) and lipoxygenase (LOX) enzymatic activity and reduces cytokine production at the mRNA level in normal, aged and damaged periodontal cells and tissues. This invention further provides a method for the prevention and treatment of diseases and conditions of the mouth, gums and teeth. The method for preventing and treating diseases and conditions of the mouth, teeth and gums is comprised of administering to a host in need thereof a therapeutically effective amount of a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from a single plant or multiple plants, preferably in the Scutellaria, Oroxyllum, Acacia or Uncaria genus of plants and pharmaceutically and/or cosmetically acceptable carriers. Finally the present invention provides a method for the prevention and treatment of diseases and conditions of the mouth, teeth or gums, including but not limited to periodontal diseases, such as gingivitis, periodontitis, pulpitis, periodontal conditions caused by the physical implantation of oral dentures, trauma, injuries, bruxism, neoplastic and other degenerative processes; material alba, pellicles, dental plaques, calculus, and stains. Use of the composition described herein also affords the benefit of maintaining optimum saliva production and pH, minimizing bacterial growth, reducing the formation of pellicles and plaque, inhibiting tooth decalcification and tooth caries (decay), promoting remineralization, which yields healthy gums, whitening teeth, maintaining healthy oral hygiene and reducing oral malodour (halitosis).

IPC 8 full level

A61K 31/35 (2006.01); **A61K 8/49** (2006.01); **A61K 8/97** (2006.01); **A61K 9/00** (2006.01); **A61K 9/14** (2006.01); **A61K 9/68** (2006.01); **A61K 31/352** (2006.01); **A61K 31/353** (2006.01); **A61K 36/11** (2006.01); **A61K 36/15** (2006.01); **A61K 36/185** (2006.01); **A61K 36/28** (2006.01); **A61K 36/47** (2006.01); **A61K 36/48** (2006.01); **A61K 36/484** (2006.01); **A61K 36/486** (2006.01); **A61K 36/53** (2006.01); **A61K 36/539** (2006.01); **A61K 36/54** (2006.01); **A61K 36/60** (2006.01); **A61K 36/906** (2006.01); **A61K 36/9062** (2006.01); **A61K 45/06** (2006.01); **A61K 47/00** (2006.01); **A61P 1/02** (2006.01); **A61Q 11/00** (2006.01)

CPC (source: EP KR)

A61K 8/498 (2013.01 - EP); **A61K 8/602** (2013.01 - EP); **A61K 9/14** (2013.01 - KR); **A61K 31/352** (2013.01 - EP); **A61K 31/353** (2013.01 - EP KR); **A61K 31/553** (2013.01 - EP); **A61K 31/7048** (2013.01 - EP); **A61K 36/11** (2013.01 - EP); **A61K 36/15** (2013.01 - EP); **A61K 36/185** (2013.01 - EP); **A61K 36/28** (2013.01 - EP); **A61K 36/47** (2013.01 - EP); **A61K 36/48** (2013.01 - EP); **A61K 36/484** (2013.01 - EP); **A61K 36/486** (2013.01 - EP); **A61K 36/53** (2013.01 - EP); **A61K 36/539** (2013.01 - EP); **A61K 36/54** (2013.01 - EP); **A61K 36/60** (2013.01 - EP); **A61K 36/906** (2013.01 - EP); **A61K 36/9062** (2013.01 - EP); **A61K 45/06** (2013.01 - EP); **A61P 1/02** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 31/04** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **A61Q 11/00** (2013.01 - EP); **A61K 2800/782** (2013.01 - EP); **Y02A 50/30** (2017.12 - EP)

Citation (search report)

- [X] JP 2003212771 A 20030730 - TAIYO KAGAKU KK, et al
- [X] WO 03092599 A2 20031113 - UNIGEN PHARMACEUTICALS INC [US]
- [A] US 6264926 B1 20010724 - FAROOQI ALAUL HASAN ABAD [IN], et al
- [Y] CHUNG C P ET AL: "PHARMACOLOGICAL EFFECTS OF METHANOLIC EXTRACT FROM THE ROOT OF SCUTELLARIA BAICALENSIS AND ITS FLAVONOIDS ON HUMAN GINGIVAL FIBROBLAST", PLANTA MEDICA, THIEME, STUTTGART, DE, vol. 61, no. 2, 1 April 1995 (1995-04-01), pages 150 - 153, XP009062689, ISSN: 0032-0943
- [Y] "Mouthwash having anticariogenicity for preventing dental caries in infants, contains barely tea containing preset amount of ascorbic acid, epigallocatechin gallate and caffeine content", WPI / THOMSON,, 1 January 1900 (1900-01-01), XP002462145
- [A] LI JI-BAO ET AL: "The effect of Radix Scutellariae on Porphyromonas endodontalis in vitro", MEDLINE,, 1 January 1900 (1900-01-01), XP002379797
- [A] NATIONAL INSTITUTE OF HEALTH SCIENCES: "Scutellaria root / Official monographs for Part II", 2001, ENGLISH VERSION OF THE JAPANESE PHARMACOPOEIA, FOURTEENTH EDITION, XP002505857
- See references of WO 2006045056A2

Citation (examination)

- US 6319523 B1 20011120 - ZHOU JAMES H [US]
- DATABASE WPI Week 198920, Derwent World Patents Index; AN 1989-147372

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)

WO 2006045056 A2 20060427; **WO 2006045056 A3 20070201**; AU 2005295190 A1 20060427; BR PI0518218 A 20081104; CA 2584124 A1 20060427; CN 101083981 A 20071205; CN 101083981 B 20130327; EP 1804787 A2 20070711; EP 1804787 A4 20090114; JP 2008517069 A 20080522; KR 20070073921 A 20070710; MX 2007004471 A 20070618; NZ 554517 A 20110225; RU 2007118535 A 20081127; TW 200630102 A 20060901

DOCDB simple family (application)

US 2005037936 W 20051019; AU 2005295190 A 20051019; BR PI0518218 A 20051019; CA 2584124 A 20051019; CN 200580043644 A 20051019; EP 05810437 A 20051019; JP 2007538073 A 20051019; KR 20077011409 A 20070518; MX 2007004471 A 20051019; NZ 55451705 A 20051019; RU 2007118535 A 20051019; TW 94136336 A 20051018